PRINCETON, N.J., May 3 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (Nasdaq: DSCI), a specialty medical device/pharmaceutical company focused on advanced wound care, will hold a conference call on May 13, 2010 to discuss the results for the first quarter ended March 31, 2010.

The conference call is scheduled to begin at 11:00 a.m. EDT (Eastern Daylight Time). The results will be released at approximately 9:00 a.m. EDT that same day.

To access the conference call, US-based listeners should dial 800-291-9234 and international listeners should dial 1-617-614-3923. All listeners should provide the following passcode: 10530567.

A webcast of the conference call will be broadcast simultaneously at http://phx.corporate-ir.net/playerlink.zhtml?c=107533&s=wm&e=3065007. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast.

Following the end of the conference call, a replay will be available through June 13, 2010, and can be accessed by dialing 888-286-8010 within the US or 617-801-6888 outside of the US. All listeners should provide the following passcode: 38923534. The webcast will also be available through June 13, 2010.

About Derma Sciences, Inc.

Derma Sciences is a global medical device and pharmaceutical company focused on wound care. Its key product, MEDIHONEY®, is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale randomized controlled trial on leg ulcers. Other key novel products introduced into the $14 billion global wound care market include XTRASORB for better management of wound exudates, and BIOGUARD for infection prevention. Derma also has in development DSC127, a novel pharmaceutical for accelerated wound healing and scar reduction. DSC127, an angiotensin analog, has shown positive healing results in multiple pre-clinical animal models. One possible mode of action of the drug is the up-regulation of mesenchymal stem cells at the wound site. Derma expects to announce the key efficacy endpoint results from this study by the end of 2010.

For more information about Derma Sciences, Inc., visit http://www.dermasciences.com.

SOURCE Derma Sciences, Inc.